37. Generalised pustular psoriasis Clinical trials / Disease details
Clinical trials : 79 / Drugs : 57 - (DrugBank : 21) / Drug target genes : 20 - Drug target pathways : 102
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2007-003922-70-DE (EUCTR) | 28/11/2007 | 08/08/2007 | Uncontrolled, open Phase IIa study to investigate efficacy and safety of efalizumab in patients with moderate to severe palmoplantar pustular psoriasis (PPP) - PPP Study | Uncontrolled, open Phase IIa study to investigate efficacy and safety of efalizumab in patients with moderate to severe palmoplantar pustular psoriasis (PPP) - PPP Study | moderate to severe palmoplantar pustular psoriasis MedDRA version: 9.1;Level: LLT;Classification code 10037159;Term: Psoriasis pustular | Trade Name: Raptiva INN or Proposed INN: Efalizumab | Technische Universität Dresden | NULL | Not Recruiting | Female: yes Male: yes | 42 | Phase 2 | Germany |